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He had no hematologic abnormalities u n t i l age 21 when h e presented with a c u t e AIHA (hgb 5.3 g/dl, haptoglobin <5 mg/dl and a 4+ p o s i t i v e d i r e c t ~oombs). After 60 mg/d of prednisone f o r 2 months, h i s hgb r o s e t o 12.8 and h i s haptoglobin t o 50 mg/dl.
However, h i s Coombs t e s t remained 4+ p o s i t i v e f o r IgG antibody and h i s r e t i c c t . was 9.7.
S t e r o i d s were discontinued and therapy with 450 mg/kg IVIG was i n i t i a t e d and continued d a i l y f o r 5 days; He was then given 100-200 mg/kg of IVIG a t 4 week i n t e r v a l s . During t h i s period, h i s hgb ranged from 12.5-14 g/dl and h i s r e t i c c t . dropped t o 0.5-2.7.
A f t e r 7 months of IVIG therapy, h i s hgb i s 12.6 g / d l , r e t i c c t . 1.65, haptoglobin 147 mg/dl and Coombs t e s t negative. These observations provide s t r o n g support f o r t h e use of h i g h dose IVIG i n immunodeficient p a t i e n t s with The e f f e c t of C. Parvum induced RES a c t i v a t i o n on I a and Fc expression of h e p a t i c nonparenchymal c e l l s (NPC) and a l v e o l a r macrophage (AM) subpopulations was studied by flow microfluoreme t r y (FMF). DBA/~J mice were i n j e c t e d I.V. w i t h 1.4 mg C.Parvum. After 14 days, NPC were i s o l a t e d by collagenase perfusion of t h e p o r t a l v e i n followed by s e p a r a t i o n on Metrizamide and F i c o l lHypaque g r a d i e n t s . AM from t h e same animals were then i s o l a t e d by t r a c h e a l lavage. Fc expression was determined by incubating i t h e c e l l s with s a t u r a t i n g concentration of r a b b i t IgG dimers followed by FITC l a b e l l e d goat anti-RIg.
I a expression was determined by HZ-specific FITC o r b i o t i n y l a t e d a n t i -I a and Texas Hemophiliac p a t i e n t s r e c e i v i n g FC have immunological abnormalities associated with AIDS. Although a high percentage of hemophiliacs have antibody t i t e r s t o HTLV-111, t h e e t i o l o g y of t h e i r a l t e r e d immune s t a t u s is unclear. W e have studied t h e i n v i t r o e f f e c t s of FC on mitogenic responses of normal p e r i p h e r a l blood mononuclear c e l l s (PBM). Ten l o t s of FC (including one heat-treated and two associated with cases of AIDS) from 5 manufacturers were assayed. These were added i n physiological concentrations t o c u l t u r e s of PBM stimulated with suboptimal and optimal concentrations of PHA (2 and 50 uglrnl, r e s p e c t i v e l y ) . Addition of t h e s e PC s i g n i f i c a n t l y reduced t h e p r o l i f e r a t i v e response i n a dose dependent manner. One Ulml FC r e s u l t e d i n an average suppression of 40% a t 2 ug/ml and 34% a t 50 ug/ml PHA. At 0.5 ~/ m l , average suppression was 35% a t 2 u g / d and 18% a t 50 uglml PHA. Two hour pre-incubation with PHA p r i o r t o a d d i t i o n of FC r e s u l t e d i n s i m i l a r suppression; however, 24 h r preincubation r e s u l t e d i n l e s s suppression. Neither column-purified Factor VIII a c t i v i t y o r antigen had s i g n i f i c a n t i n h i b i t o r y e f f e c t s . C e l l v i a b i l i t i e s i n FC c u l t u r e s were s i m i l a r t o c o n t r o l c u l t u r e s . These r e s u l t s suggest t h a t commericially a v a i l a b l e FC contains a f a c t o r ( s 1 o t h e r than HTLV-I11 which i n h i b i t s the p r o l i f e r a t i v e responses of-normal lymphocytes. E f f o r t s t o i s o l a t e t h i s f a c t o r ( s ) a r e c u r r e n t l y i n progress. 
IL-2 has been shown t o have immunorestorative c a p a b i l i t i e s i n some animal and human systems of acquired immunodeficiency. In t h i s r e p o r t , we present our i n v e s t i g a t i o n s i n t o t h e e f f i c a c y o f
recombinant IL-2 in v i t r o i n p a t i e n t s with primary immunodeficiency. 4/4 p a t i e n t s with DiGeorge syndrome were found t o have d e f i c i e n t NK c e l l function (K562 l y s i s was 33-58% o f c o n t r o l s , p < 0.01). The DiGeorge p a t i e n t s a l s o had decreased production of IL-2 a f t e r PHA s t i m u l a t i o n (4/4 had < 50% o f normal c o n t r o l s , p < 0.02).
Both of these parameters, however, were improved i n 4/4 DiGeorge p a t i e n t s up t o normal l e v e l s a f t e r incubation of t h e i r lymphocytes i n IL-2 f o r 2 days (K562 l y s i s was now 85-104% and IL-2 production was > 90% of the c o n t r o l s , with the p value versus c o n t r o l s now z 0.3). Lymphocytes of 7 o t h e r p a t i e n t s with a v a r i e t y of B c e l l and T c e l l acquired and primary immunod e f i c i e n c i e s were t e s t e d simultaneously i n these assays t o determine t h e s p e c i f i c i t y of t h e improvements seen i n t h e d e f e c t s of the DiGeorge p a t i e n t s . Depending upon the c l i n i c a l s t a t u s and s p e c i f i c immune d e f e c t i n the p a t i e n t s t e s t e d , t h e i r NK c e l l function and/or IL-2 production was d e f i c i e n t ( p < 0.01).
However, none o f t h e d e f e c t s seen i n these 7 p a t i e n t s were c o r r e c t a b l e by incubation i n IL-2 ( p < 0.01). Thus, s p e c i f i c a l l y i n DiGeorge p a t i e n t s , d e f e c t s i n N K c e l l function and IL-2 production can be corrected by incubation i n IL-2. I t i s possible t h a t t h e administration o f IL-2 i n vivo may play a r o l e i n the immunorestorative therapy of DiGeorge p a t i e n t s . 
We previously showed t h a t orally-administered bovine IgG antibodies r e s i s t p r o t e o l y s i s and provide s p e c i f i c immune protection. I n t h i s r e p o r t we use s p e c i f i c anti-Pb bovine IgG t o reduce t h e m o r t a l i t y of Pb s e p s i s i n an immunocompromised host. We used a leukopenic mouse model t o e v a l u a t e t h e p r o t e c t i v e e f f e c t of orally-administered anti-Pb bovine c o l o s t r a l (BCI) and human serum (HISG) IgG and t h r e e o t h e r a n t i m i c r o b i a l f a c t o r s -l a c t o -
f e r r i n (LF) , lysozyme (LZ) and lactoperoxidase (LP) . Leukopenic mice (cyclophosphamide, 300 mglkg) were f e d anti-Pb BCI, c o n t r o l BCI, commercial HISG, LF, LZ, LP, o r a 5% glucose s o l u t i o n (D5W) over a 6-day period. Anti-Pb BCI, c o n t r o l BCI, and HISG had anti-Pb a c t i v i t y by ELISA, a g g l u t i n a t i o n , and complement fixat i o n assays. On day 4 of feedings, t h e mice were orally-inocul a t e d w i t h l o 6 Pb. aenuginona (serotype 10). Mortality was recorded 24, 48 and 72 hours l a t e r . Group s u r v i v a l curves were n o t equal (p<O. 01 ; Kruskal-Wallis) . P a i r e d comparison t e s t s f o r the anti-Pb BCI and D5W groups showed a decrease i n m o r t a l i t y of ~5 0 % (p<0.05). Groups f e d c o n t r o l BCI o r HISG, which e x h i b i t l e s s anti-Pb a c t i v i t y , had intermediate reductions i n m o r t a l i t y . The m o r t a l i t y of groups fed LF, LZ, o r LP was not d i f f e r e n t from t h e D5W group. We conclude t h a t o r a l anti-Pb BCI reduces t h e m o r t a l i t y of Pb s e p s i s i n a murine model of leukopenia. W e specu l a t e t h a t o r a l a n t i b o d i e s t o e n t e r i c organisms may be an e f f e ct i v e means of reducing t h e incidence and s e v e r i t y of gram negative s e p s i s i n leukopenic hosts. r c h i l d r e n with severe combined immunodeficiencv d i s e a s e have received bone marrow t r a n s p l a n t s from a haplotype mismatched parent.
The marrow was t r e a t e d by monoclonal antibody and complement p r i o r t o infusion. Complicating f a c t o r s involved t h e presence of p r i o r maternal g r a f t versus host i n 1 , p r i o r thymus t r a n s p l a n t a t i o n i n 1 and presence o f s u f f i c i e n t n a t i v e immunity t o r e q u i r e a b l a t i o n i n one. Two c h i l d r e n died without engraftment. The s u r v i v o r s have B and T c e l l engraftment a s demonstrated by normal i n v i t r o T c e l l pro1 i f e r a t i v e responses, normal immunoglobulin and/or functional antibody l e v e l s except one o f t h e p a t i e n t s appears t o have IgA deficiency. The l o n g e s t period o f follow up i s 20 months and t h e s h o r t e s t i s t h r e e months. In 1 p a t i e n t , thymus biopsy a f t e r t r a n s p l a n t confirmed a normal d i s t r i b u t i o n of c e l l s and t h e presence o f a marker f o r d e n d r i t i c c e l l s . This marker was not present i n a p a t i e n t who was not s u c c e s s f u l l y engrafted.
These data show: 1 . Successful engraftment can be accomplished with haplotype mismatched marrow even i n t h e f a c e of maternal g r a f t versus host d i s e a s e . 2 . Haplotype mismatched marrow can home t o t h e host thymus and be a p p r o p r i a t e l y d i f f e re n t i a t e d . 3. C r i t e r i a f o r p r i o r a b l a t i v e therapy need t o be e s t a b l i s h e d ; thymus imnunohistochemistry may be helpful i n t h i s regard. 4. Mechanisms of t h e imnune response can be i n f e r r e d from t h e nature o f t h e r e c o n s t i t u t i o n .
